Atossa Therapeutics
ATOS
83 hedge funds and large institutions have $19.1M invested in Atossa Therapeutics in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 29 reducing their positions, and 12 closing their positions.
112% more call options, than puts
Call options by funds: $123K | Put options by funds: $58K
0.12% less ownership
Funds ownership: 1.59% → 1.46% (-0.12%)
3% less funds holding
Funds holding: 86 → 83 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
32% less capital invested
Capital invested by funds: $28.3M → $19.1M (-$9.17M)
38% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$388K |
| 2 |
Renaissance Technologies
New York
|
+$241K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$173K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$97.9K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$34.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$542K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$346K |
| 3 |
VF
Virtu Financial
New York
|
-$197K |
| 4 |
JP Morgan Chase
New York
|
-$196K |
| 5 |
Morgan Stanley
New York
|
-$136K |
ATOS Hedge Fund Activity: Q1 2025 in Review
83 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2025, worth a combined $19.1M — down 32% from $28.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATOS and 9 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 18 added.
The largest buyer was Squarepoint, opening a new position worth an estimated $388K. The largest seller was UBS Group, cutting an estimated $542K.
- 83 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2025, down from 86 in Q4 2024.
- Funds reported $19.1M of Atossa Therapeutics stock for Q1 2025, down 32% quarter-over-quarter.
- 9 funds opened new Atossa Therapeutics positions in Q1 2025 and 12 closed out, a net change of -3 holders.
- The largest Atossa Therapeutics buyer in Q1 2025 was Squarepoint, an estimated $388K added.
- The largest Atossa Therapeutics seller in Q1 2025 was UBS Group, an estimated $542K sold.
Based on aggregated 13F filings for Q1 2025.